ClinicalTrials.gg
Active, not recruitingNCT03974022Updated Jan 29, 2026Results posted

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

A Phase 1/2 interventional study of Sunvozertinib in Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Active, not recruiting at 124 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
315
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 12 under way, 2 of them phase 3. sunvozertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 13
315 · median 100
Started
2019
the only one that year
Phase 1/2
2 of 13
1 open now
Primary completion
2024-07
later than 1 of 11 live
Registered
1st of 13
by date
Lead sponsor
5 of 13
Dizal Pharmaceuticals

Among the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, reaches primary completion later than 1 of the 11 other live ones, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sunvozertinib

sunvozertinib: first FDA approval 2025 (ZEGFROVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.

Read the detailed description

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of Sunvozertinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation, dose expansion, food effect (Part A) and dose extension (Part B).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • EGFR
  • HER2
  • mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged at least 18 years old, be able to provide a signed and dated, written .
  2. With documented histological or cytological confirmed locally advanced or NSCLC with EGFR or mutations.
  3. () performance status 0-1.
  4. Predicted ≥ 12 weeks
  5. Patient must have according to 1.1.
  6. Patients with (BM) can be enrolled under the condition that BM is previously treated and stable, neurologically asymptomatic and does not require treatment.
  7. Adequate organ system function.
  8. Part A Dose expansion: Dose expansion cohort 5: NSCLC patients with EGFR Exon20ins, who have not received prior systemic therapy (treatment naïve).

    Part B Dose extension:

  9. Patients must have or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR Exon20ins mutation in tumor tissue from a local CLIA-certified laboratory (or equivalent) or Sponsor designated central laboratory prior to the study entry.
  10. Patients should have received at least 1 line, but no more than 3 for metastatic/locally advanced disease.

Exclusion criteria

Exclusion Criteria:

  1. For part B: Patients who have received prior treatment with Poziotinib or TAK788 or other EGFR/ exon20 insertion inhibitors should be excluded. Prior treatment with currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as gefitinib, erlotinib, osimertinib, afatinib and dacomitinib, are allowed unless the patient had an objective response and subsequent progression assessed by the investigator.
  2. Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular access), or onco-immunotherapy (e.g. PD-1, PD-L1, CTLA-4) within 4 weeks before the first administration of Sunvozertinib.
  3. Any cytotoxic chemotherapy, agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before the first administration.
  4. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before the first administration.
  5. Receiving (or unable to stop using) medications or herbal supplements known to be potent inhibitors or inducers of within 1-2 weeks before the first administration.
  6. Any unresolved toxicities from prior therapy greater than grade 1 at the time of starting Sunvozertinib with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
  7. Spinal cord compression or .
  8. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including , , (HIV) and COVID-19 (per local practice).
  9. Any of the following cardiac criteria: (1) Mean resting interval (QTc) > 470 msec obtained from 3 (ECGs); (2) Any abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec. (3) Any factors that increase the risk of QTF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval; (4) Prior history of atrial fibrillation within 6 months of first administration of Sunvozertinib, except prior drug treatment related and recovered.
  10. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  11. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Sunvozertinib.
  12. History of to active or inactive of Sunvozertinib or drugs with a similar chemical structure or class to Sunvozertinib.
  13. Women who are pregnant or breast feeding.
  14. Involvement in the planning and conduct of the study.
  15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    Part A Dose escalation

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 1

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 2

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 3

    Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 4

    Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 5

    Patients with EGFR Exon20ins, treatment naïve

    Drug: Sunvozertinib

  • Experimental
    Part A Dose expansion cohort 6

    Drug: Sunvozertinib

  • Experimental
    Part B Dose extension cohort 1

    Patients with EGFR Exon20ins

    Drug: Sunvozertinib

  • Experimental
    Part B Dose extension cohort 2

    Patients with EGFR Exon20ins

    Drug: Sunvozertinib

Interventions

  • Daily dose of Sunvozertinib

    Also known as: DZD9008

06

What researchers measure

Primary outcomes

  1. Part A Dose Escalation: Dose Limiting Toxicities (DLTs).

    To evaluate the safety and tolerability and defined the maximum tolerated dose (MTD) of sunvozertinib. DLT was evaluated in the DLT observation frame.

    Time frame: The DLT observation period is defined as the 28 days after the first multiple dose (up to 36 days from baseline).

  2. Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).

    To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).

    Time frame: through the study completion, an average of around 1 year for part B

Secondary outcomes

  1. Part B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1

    To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.

    Time frame: Through the study completion, an average of around 1 year for part B

  2. Part B: DoR, PFS According to RECIST 1.1 Using Assessments Performed by an IRC; DoR, PFS Using Investigators Assessments According to RECIST 1.1

    To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.

    Time frame: Through the study completion, an average of around 1 year for part B

  3. Part B: AEs/SAEs

    To determine the safety and tolerability of Sunvozertinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.

    Time frame: Through the study completion, an average of around 1 year for part B

  4. Part A: Confirmed ORR and DCR by Investigator.

    To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. Confirmed ORR was defined as the percentage of patients achieving a CR (Complete Response) or PR (Partial Response) and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by a subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.

    Time frame: The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.

  5. Part A: DoR and PFS by Investigator.

    To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. DoR was presented for patients with confirmed objective response (CR or PR). DoR was the time from date of first documentation of CR or PR, which was subsequently confirmed, to date of first documentation of objective progression or death. Patients who had no documentation of objective progression or death was censored. PFS was the time from first dose date of sunvozertinib to date of first documentation of progression or death due to any cause, whichever occurred first. Patient who had no PFS event was censored.

    Time frame: The maximum median of DoR was 19.3 months, and the maximum median of PFS was 12.5 months for part A.

  6. Part A: Confirmed ORR and DCR by Independent Review Committee (IRC).

    To retrospectively assess anti-tumor activity of sunvozertinib in treatment-naive NSCLC patients with EGFR Exon20ins according to RECIST 1.1 by IRC. Confirmed ORR was defined as the percentage of patients achieving a CR or PR and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.

    Time frame: The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.

  7. Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008

    Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the single dose.

    Time frame: Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)

  8. Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.

    Time frame: Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)

  9. Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008

    Maximum observed plasma concentration(ng/mL), at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.

    Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose expansion and expansion)

  10. Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008

    Area under the plasma concentration-time curve in the dose interval at steady state, calculated by the linear up/log down rule.

    Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose escalation and expansion)

  11. Part A Food Effect: Maximum Plasma Concentration (Cmax) of DZD9008

    Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose, in the fasted or fed state.

    Time frame: Day 1 and Day 9: 0 (predose) up to 168 hours.

  12. Part A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008

    Area under the plasma concentration-time-curve from time zero the last quantifiable time point, calculated by the linear up/log down rule, in the fasted or fed state.

    Time frame: Day 1 and Day 9: 0 (predose) up to 168 hours.

  13. Part B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753

    Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.

    Time frame: Cycle 1 Day 1: 0 (predose) up to 24 hours

  14. Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753.

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.

    Time frame: Cycle 1 Day 1: 0 (predose) up to 24 hours

  15. Part B: Cmax,ss, at Steady State of DZD9008 and DZ0753

    Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.

    Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours

  16. Part B: AUCss, at Steady State of DZD9008 and DZ0753.

    Area under the plasma concentration-time curve from time zero in the dose interval at steady state, calculated by the linear up/log down rule.

    Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours

07

Results

Posted Dec 3, 2025

Participant flow

Participant flow — Overall Study
MilestonePart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Started3637610141473105791111
Completed3535558103240465461
Not completed01021564470113750
Withdrew: Death01020102140003340
Withdrew: Withdrawal by subject000004422301039
Withdrew: Lost to follow-up000000100000011
Withdrew: Site terminated by sponsor or non compliance000010101000100

Outcome measures

PrimaryPart A Dose Escalation: Dose Limiting Toxicities (DLTs).

To evaluate the safety and tolerability and defined the maximum tolerated dose (MTD) of sunvozertinib. DLT was evaluated in the DLT observation frame.

Time frame:
The DLT observation period is defined as the 28 days after the first multiple dose (up to 36 days from baseline).
Reported as:
Count of participants · Participants
Part A Dose Escalation: Dose Limiting Toxicities (DLTs).
ParticipantsPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mg
Part A Dose Escalation: Dose Limiting Toxicities (DLTs).00011
PrimaryPart B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).

To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).

Time frame:
through the study completion, an average of around 1 year for part B
Reported as:
Number · percentage of participants
Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).
percentage of participantsPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).45.9 (33.6 to 58.5)45.8 (34.8 to 57.0)
Statistical analysis
  • Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg · binomial exact test against H0 · p = <0.0001
  • Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg · binomial exact test against H0 · p = <0.0001
SecondaryPart B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1

To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.

Time frame:
Through the study completion, an average of around 1 year for part B
Reported as:
Number · percentage of participants
Part B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1
percentage of participantsPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
confirmed DCR by IRC89.4 (80.8 to 95.0)88.8 (81.2 to 94.1)
confirmed DCR by investigator88.2 (79.4 to 94.2)88.8 (81.2 to 94.1)
SecondaryPart B: DoR, PFS According to RECIST 1.1 Using Assessments Performed by an IRC; DoR, PFS Using Investigators Assessments According to RECIST 1.1

To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.

Time frame:
Through the study completion, an average of around 1 year for part B
Reported as:
Median · months
Part B: DoR, PFS According to RECIST 1.1 Using Assessments Performed by an IRC; DoR, PFS Using Investigators Assessments According to RECIST 1.1
monthsPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Median duration of response (IRC)NA (7.2 to NA)NA (6.7 to NA)
Median duration of response (investigator)8.3 (7.0 to NA)8.8 (5.3 to 18.0)
Median progression free survival (IRC)8.4 (6.8 to 11.2)6.9 (5.6 to 11.0)
Median progression free survival (investigator)8.3 (5.5 to 10.9)6.8 (5.5 to 8.3)
SecondaryPart B: AEs/SAEs

To determine the safety and tolerability of Sunvozertinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.

Time frame:
Through the study completion, an average of around 1 year for part B
Reported as:
Number · participants
Part B: AEs/SAEs
participantsPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Any TEAE91111
Any treatment- emergent SAE3741
SecondaryPart A: Confirmed ORR and DCR by Investigator.

To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. Confirmed ORR was defined as the percentage of patients achieving a CR (Complete Response) or PR (Partial Response) and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by a subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.

Time frame:
The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.
Reported as:
Number · percentage of participants
Part A: Confirmed ORR and DCR by Investigator.
percentage of participantsPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal
Confirmed objective response rate0 (0.0 to 70.8)16.7 (0.4 to 64.1)0 (0.0 to 70.8)42.9 (9.9 to 81.6)0 (0.0 to 52.2)50 (18.7 to 81.3)30.8 (9.1 to 61.4)21.4 (4.7 to 50.8)40.0 (5.3 to 85.3)55.2 (35.7 to 73.6)—20.0 (0.5 to 71.6)14.3 (0.4 to 57.9)
Confirmed disease control rate100.0 (29.2 to 100.0)50.0 (11.8 to 88.2)66.7 (9.4 to 99.2)71.4 (29.0 to 96.3)60.0 (14.7 to 94.7)80 (44.4 to 97.5)84.6 (54.6 to 98.1)92.9 (66.1 to 99.8)80.0 (28.4 to 99.5)93.1 (77.2 to 99.2)—60.0 (14.7 to 94.7)85.7 (42.1 to 99.6)
SecondaryPart A: DoR and PFS by Investigator.

To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. DoR was presented for patients with confirmed objective response (CR or PR). DoR was the time from date of first documentation of CR or PR, which was subsequently confirmed, to date of first documentation of objective progression or death. Patients who had no documentation of objective progression or death was censored. PFS was the time from first dose date of sunvozertinib to date of first documentation of progression or death due to any cause, whichever occurred first. Patient who had no PFS event was censored.

Time frame:
The maximum median of DoR was 19.3 months, and the maximum median of PFS was 12.5 months for part A.
Reported as:
Median · month
Part A: DoR and PFS by Investigator.
monthPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal
Median duration of response(month)NA (NA to NA)4.0 (NA to NA)NA (NA to NA)5.5 (2.8 to 5.5)NA (NA to NA)NA (3.2 to NA)4.2 (3.2 to NA)6.3 (2.8 to 23.4)4.3 (3.0 to 5.6)9.8 (5.6 to NA)—19.3 (NA to NA)5.6 (NA to NA)
Median progression free survival(month)3.1 (3.1 to 9.6)1.9 (0.9 to 22.5)12.5 (1.7 to NA)3.3 (1.2 to 7.4)4.6 (1.0 to 6.0)4.9 (1.2 to NA)5.5 (4.0 to 12.7)4.2 (2.4 to 9.0)4.2 (1.4 to NA)10.8 (5.5 to 12.5)—3.3 (1.4 to 21.3)5.3 (3.2 to NA)
SecondaryPart A: Confirmed ORR and DCR by Independent Review Committee (IRC).

To retrospectively assess anti-tumor activity of sunvozertinib in treatment-naive NSCLC patients with EGFR Exon20ins according to RECIST 1.1 by IRC. Confirmed ORR was defined as the percentage of patients achieving a CR or PR and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.

Time frame:
The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.
Reported as:
Number · percentage of participants
Part A: Confirmed ORR and DCR by Independent Review Committee (IRC).
percentage of participantsPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal
Confirmed objective response rate62.1 (42.3 to 79.3)
Confirmed disease control rate89.7 (72.6 to 97.8)
SecondaryPart A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008

Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the single dose.

Time frame:
Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)
Reported as:
Geometric mean · ng/mL
Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008
ng/mLPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg Daily
Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD900838.95 ± 37.389.19 ± 53.5NA ± NA428.8 ± 69.2167.8 ± 90.7176.3 ± 50.7286.7 ± 62.6253.0 ± 44.1346.5 ± 33.5354.3 ± 68.3—
SecondaryPart A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008

Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.

Time frame:
Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)
Reported as:
Geometric mean · h*ng/mL
Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008
h*ng/mLPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg
Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD90081434 ± 45.92693 ± 115.8NA ± NA12540 ± 69.76419 ± 60.02300 ± 46.03800 ± 56.93313 ± 39.34517 ± 28.24338 ± 60.3—
SecondaryPart A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008

Maximum observed plasma concentration(ng/mL), at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.

Time frame:
Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose expansion and expansion)
Reported as:
Geometric mean · ng/mL
Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008
ng/mLPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg
Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD900882.85 ± 17.2229.4 ± 50.6NA ± NA590.2 ± 80.9677.0 ± 21.9358.0 ± 53.4717.5 ± 40.9613.3 ± 48.8819.3 ± 57.3716.5 ± 41.7—
SecondaryPart A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008

Area under the plasma concentration-time curve in the dose interval at steady state, calculated by the linear up/log down rule.

Time frame:
Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose escalation and expansion)
Reported as:
Geometric mean · h*ng/mL
Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008
h*ng/mLPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg
Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD90081506 ± 13.23823 ± 55.6NA ± NA10240 ± 78.112030 ± 25.25906 ± 52.311630 ± 40.39949 ± 45.814170 ± 47.912030 ± 40.2—
SecondaryPart A Food Effect: Maximum Plasma Concentration (Cmax) of DZD9008

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose, in the fasted or fed state.

Time frame:
Day 1 and Day 9: 0 (predose) up to 168 hours.
Reported as:
Geometric mean · ng/mL
Part A Food Effect: Maximum Plasma Concentration (Cmax) of DZD9008
ng/mLPart A Food Effect Cohort: Sunvozertinib 300 mg
Part A Food effect: Maximum Plasma Concentration (Cmax) of DZD9008 under Fasted condition307.0 ± 59.6
Part A Food effect: Maximum Plasma Concentration (Cmax) of DZD9008 under High-Fat Meal condition331.6 ± 48.8
SecondaryPart A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008

Area under the plasma concentration-time-curve from time zero the last quantifiable time point, calculated by the linear up/log down rule, in the fasted or fed state.

Time frame:
Day 1 and Day 9: 0 (predose) up to 168 hours.
Reported as:
Geometric mean · h*ng/mL
Part A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008
h*ng/mLPart A Food Effect Cohort: Sunvozertinib 300 mg
Part A Food effect: AUC0-t of DZD9008 under Fasted condition8266 ± 65.8
Part A Food effect: AUC0-t of DZD9008 under High-Fat Meal condition10050 ± 67.5
SecondaryPart B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.

Time frame:
Cycle 1 Day 1: 0 (predose) up to 24 hours
Reported as:
Geometric mean · ng/mL
Part B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753
ng/mLPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Part B: Maximum Plasma Concentration (Cmax) of DZD9008173.4 ± 80.4325.8 ± 73.7
Part B: Maximum Plasma Concentration (Cmax) of DZ075318.90 ± 113.440.40 ± 78.2
SecondaryPart B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753.

Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.

Time frame:
Cycle 1 Day 1: 0 (predose) up to 24 hours
Reported as:
Geometric mean · h*ng/mL
Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753.
h*ng/mLPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Part B: AUC0-t of DZD90082423 ± 71.94397 ± 55.7
Part B: AUC0-t of DZ0753200.4 ± 125.2448.5 ± 69.9
SecondaryPart B: Cmax,ss, at Steady State of DZD9008 and DZ0753

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.

Time frame:
Cycle 2 Day 1: 0 (predose) up to 24 hours
Reported as:
Geometric mean · ng/mL
Part B: Cmax,ss, at Steady State of DZD9008 and DZ0753
ng/mLPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Part B: Maximum Plasma Concentration (Cmax,ss) of DZD9008342.8 ± 57.4642.3 ± 48.1
Part B: Maximum Plasma Concentration (Cmax,ss) of DZ075342.58 ± 108.0112.4 ± 83.7
SecondaryPart B: AUCss, at Steady State of DZD9008 and DZ0753.

Area under the plasma concentration-time curve from time zero in the dose interval at steady state, calculated by the linear up/log down rule.

Time frame:
Cycle 2 Day 1: 0 (predose) up to 24 hours
Reported as:
Geometric mean · h*ng/mL
Part B: AUCss, at Steady State of DZD9008 and DZ0753.
h*ng/mLPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
Part B: AUCss, at Steady State of DZD90086286 ± 56.110230 ± 47.5
Part B: AUCss, at Steady State of DZ0753728.9 ± 112.21722 ± 84.9

Adverse events

Collected over Survival data continued to be collected for Part B participants following treatment discontinuation. SAEs and other AEs were monitored from the study treatment until the end of treatment, an average of approximately 11 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg2/7 (28.6%)4/7 (57.1%)7/7 (100%)
Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State1/10 (10%)4/10 (40%)10/10 (100%)
Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State0/14 (0%)5/14 (35.7%)14/14 (100%)
Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal2/14 (14.3%)9/14 (64.3%)14/14 (100%)
Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal1/7 (14.3%)2/7 (28.6%)7/7 (100%)
Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal4/31 (12.9%)14/31 (45.2%)31/31 (100%)
Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg———
Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted0/5 (0%)0/5 (0%)5/5 (100%)
Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal0/7 (0%)1/7 (14.3%)7/7 (100%)
Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg33/91 (36.3%)37/91 (40.7%)91/91 (100%)
Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg40/111 (36%)41/111 (36.9%)111/111 (100%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
PneumoniaInfections and infestations0/30/61/32/71/60/101/141/140/71/31—0/50/76/916/111
DysarthriaNervous system disorders0/30/61/30/70/60/100/140/140/70/31—0/50/70/910/111
Aortic valve stenosisCardiac disorders0/31/60/30/70/60/100/140/140/70/31—0/50/70/910/111
ArrhythmiaCardiac disorders0/30/60/30/71/60/100/140/140/70/31—0/50/70/910/111
DeathGeneral disorders0/31/60/30/70/60/100/140/140/70/31—0/50/70/910/111
Generalised oedemaGeneral disorders0/30/60/30/71/60/100/140/140/70/31—0/50/70/910/111
Iron deficiency anaemiaBlood and lymphatic system disorders0/30/60/31/70/60/100/140/140/70/31—0/50/70/910/111
TachycardiaCardiac disorders0/30/60/30/70/60/100/140/140/70/31—0/51/70/910/111
DiarrhoeaGastrointestinal disorders0/30/60/31/70/60/100/140/140/71/31—0/50/70/919/111
Pancreatic enzyme abnormalityGastrointestinal disorders0/30/60/30/70/60/100/140/141/70/31—0/50/70/910/111
Most frequent other events
Showing 10 of 270
Most frequent other events
EventPart A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg
DiarrhoeaGastrointestinal disorders0/32/62/34/75/67/1012/1412/147/725/31—3/55/765/9194/111
VomitingGastrointestinal disorders0/30/61/33/75/61/106/143/141/77/31—0/51/732/9149/111
NauseaGastrointestinal disorders0/31/60/32/73/62/107/146/143/75/31—4/54/728/9148/111
ConstipationGastrointestinal disorders0/32/62/32/71/62/102/145/142/77/31—1/50/725/9116/111
FatigueGeneral disorders2/31/61/30/73/60/103/146/141/75/31—2/53/724/9122/111
ArthralgiaMusculoskeletal and connective tissue disorders2/30/60/30/70/60/100/140/141/74/31—0/51/78/916/111
Dermatitis acneiformSkin and subcutaneous tissue disorders0/30/62/33/71/60/103/142/142/77/31—0/52/77/918/111
RashSkin and subcutaneous tissue disorders2/31/60/30/73/61/104/146/141/716/31—1/50/734/9152/111
StomatitisGastrointestinal disorders0/30/61/30/70/62/101/144/144/710/31—0/50/718/9122/111
PyrexiaGeneral disorders0/30/60/31/70/63/102/140/144/70/31—0/50/77/918/111

Baseline characteristics

No patient was enrolled in Part A dose expansion cohort 6 due to conflict with enrollment of Part B.

Age, Continuous
Age, Continuous(years)Part A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mgTotal
Median48.0 (38 to 72)62.0 (48 to 83)57.0 (55 to 74)64.0 (57 to 82)63.5 (48 to 85)61 (41 to 83)62.5 (41 to 76)60.5 (34 to 73)64 (38 to 73)61 (37 to 96)—44.0 (39 to 82)65.0 (55 to 78)62 (35 to 88)64 (37 to 89)62.0 (34 to 96)
Sex: Female, Male
Sex: Female, Male(Participants)Part A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mgTotal
Female332347692130466163186
Male031423855180113048129
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Dose Escalation Cohort 1: Sunvozertinib 50 mgPart A Dose Escalation Cohort 2: Sunvozertinib 100 mgPart A Dose Escalation Cohort 3: Sunvozertinib 200 mgPart A Dose Escalation Cohort 4: Sunvozertinib 300 mgPart A Dose Escalation Cohort 5: Sunvozertinib 400 mgPart A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted StatePart A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat MealPart A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat MealPart A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mgPart A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then FastedPart A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat MealPart B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mgPart B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mgTotal
American Indian or Alaska Native0000000000000000
Asian25253109137230105965204
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American0000000001000023
White11123051050463044103
More than one race0000000000000000
Unknown or Not Reported0000000002001205
08

Study locations

124 sites

Showing the first 100 of 124 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Janne PA; WU-KONG1B. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). J Clin Oncol. 2025 Oct 10;43(29):3198-3208. doi: 10.1200/JCO-25-00788. Epub 2025 Sep 9. PubMed 40923280 ↗
  • Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, Pisick E, Nguyen D, Malhotra J, Reyes A, Salgia R. Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12;6(9):100803. doi: 10.1016/j.medj.2025.100803. Epub 2025 Aug 8. PubMed 40782807 ↗
  • Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, Zhou C. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep 1;35(8):757-760. doi: 10.1097/CAD.0000000000001628. Epub 2024 Jun 26. PubMed 38924456 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jul 2024, 60 months.

Results were first posted in Dec 2025, 1 year 4 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 60 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
Jun 4, 2019
StartActual
Jul 9, 2019
Primary completionActual
Jul 29, 2024
CompletionEst.
Dec 2026
Results first posted
Dec 3, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03974022
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Jul 9, 2019
Primary completion
Jul 29, 2024
Completion
Dec 2026 (estimated)
Results posted
Dec 3, 2025
Last update
Jan 29, 2026

Study contacts

Pasi Antero Jänne, M.D & Ph. D
principal investigator · Dana-Farber Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunvozertinib

Start the discussion